Maintenance of visual functions in patients with a scheduled cataract surgery
DOI: 10.32364/2311-7729-2020-20-3-117-121
Maintenance of visual functions in patients with a scheduled cataract surgery
I.A. Il’inskaya1, S.Yu. Kopaev2
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2S.N. Fedorov NMRC “MNTK “Eye Microsurgery”, Moscow, Russian Federation
Aim: to evaluate the maintenance of visual functions by administering eye drops which prevent lens opacities in patients with a scheduled cataract surgery based on the stages of cataract development.
Patients and Methods: 822 patients with a scheduled cataract surgery were recommended with the instillations of Catalin® (1 drop four times daily). The patients were divided into two groups, i.e., the study group (364 patients who used the eye drops throughout the waiting time) and the control group (195 patients who refused the eye drops for various reasons). Both groups were additionally subdivided into three subgroups, i.e., I (mature cataract), II (immature cataract), and III (early cataract). Exclusion criteria (n=263) were irregular instillations or the use of Catalin® analogues.
Results: the average waiting time was 6.76±1.35 months. A decrease in uncorrected visual acuity (UCVA) by 37% and 40% was revealed
in the study group and the control group, respectively. Additionally, a myopic shift of the spherical equivalent was detected. Significant differences (р<0.001) were revealed in subgroup II, i.e., less changes in the spherical equivalent as compared with the control group and subgroup III. Meanwhile, the changes in UCVA were significantly less in the study group as compared with the control group.
Conclusion: Catalin® (Senju Pharmaceutical) is effective in early cataract. In immature cataract, this drug slows down refractive changes. In mature cataract, Catalin® is ineffective. In these patients, the earliest possible cataract surgery is required.
Keywords: vision loss, cataract, spherical equivalent, pirenoxine, cataract treatment, cataract surgery.
For citation: Il’inskaya I.A., Kopaev S.Yu. Maintenance of visual functions in patients with a sa scheduled cataract surgery. Russian Journal of Clinical Ophthalmology. 2020;20(3):117–121. DOI: 10.32364/2311-7729-2020-20-3-117-121.
2. Libman E.S., Shakova E.V. Blindness and disability due to pathology of the organ of vision in Russia. Vestnik oftalmologii. 2006;1:35–37 (in Russ.).
3. Parisi A.V., Downs N. Cloud cover and horizontal plane eye damaging solar IIV exposures. Invest. J. Biometeorol. 2004;49(2):130–136. DOI: 10.1007/s00484-004-0213-7.
4. Maliugin B.E. State of the art cataract surgery and intraocular optical correction. Vestnik oftalmologii. 2014;130(6):80–88 (in Russ.).
5. Reddy J.C., Vaddavalli P.K., Sharma N., Sachdev M.S. et al. A new normal with cataract surgery during COVID-19 pandemic. Indian J Ophthalmol. 2020;68(7):1269–1276. DOI: 10.4103/ijo.IJO_1528_20.
6. Kohnen Т. The new normal for cataract and refractive surgery due to COVID-19 (SARS-CoV-2). J Cataract Refract Surg. 2020;46(6):809–810. DOI: 10.1097/j.jcrs.0000000000000240.
7. Napoli P.E., Nioi M., D’Aloja E., Fossarello M. Safety Recommendations and Medical Liability in Ocular Surgery during the COVID-19 Pandemic: An Unsolved Dilemma. J Clin Med. 2020;9(5):1403. DOI: 10.3390/jcm9051403.
8. Oganezova J.G. The use of the drug Catalin in the treatment of age-related cataracts. Klinicheskaja оftal’mologija. 2013;2:74–77 (in Russ.).
9. Polunin G.S., Makarov I.A., Bubnova I.A. Klinicheskaja oftal’mologija. 2012;3:110–114 (in Russ.).
10. Oganezova J.G., Egorov E.A. Catalin: effective eye drops for the treatment of senile cataract. Klinicheskaja oftal’mologija. 2014;3:176–179 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
